Head-To-Head Comparison: PetVivo (OTCMKTS:PETV) and Boston Scientific (NYSE:BSX)
Head-To-Head Comparison: PetVivo (OTCMKTS:PETV) and Boston Scientific (NYSE:BSX)
Boston Scientific (NYSE:BSX – Get Rating) and PetVivo (OTCMKTS:PETV – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.
波士顿科学公司(NYSE：BSX-GET Rating)和PetVivo(OTCMKTS：PETV-GET Rating)都是医疗公司，但哪只股票更好？我们将根据两家公司的股息、风险、机构所有权、收益、分析师建议、估值和盈利能力来比较它们的实力。
Analyst Ratings
分析师评级
This is a summary of recent ratings and recommmendations for Boston Scientific and PetVivo, as reported by MarketBeat.com.
据MarketBeat.com报道，这是波士顿科学公司和PetVivo公司最近的评级和推荐摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Boston Scientific | 0 | 1 | 10 | 1 | 3.00 |
| PetVivo | 0 | 0 | 1 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 波士顿科学公司 | 0 | 1 | 10 | 1 | 3.00 |
| PetVivo | 0 | 0 | 1 | 0 | 3.00 |
Boston Scientific currently has a consensus price target of $46.55, indicating a potential upside of 13.11%. PetVivo has a consensus price target of $7.00, indicating a potential upside of 178.88%. Given PetVivo's higher possible upside, analysts plainly believe PetVivo is more favorable than Boston Scientific.
波士顿科学公司目前的共识目标价为46.55美元，表明潜在上行幅度为13.11%。PetVivo的一致目标价为7美元，表明潜在涨幅为178.88%。考虑到PetVivo更有可能的上行空间，分析师们显然认为PetVivo比波士顿科学公司更有利。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Boston Scientific | 7.16% | 14.58% | 7.60% |
| PetVivo | -3,817.65% | -99.68% | -82.24% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 波士顿科学公司 | 7.16% | 14.58% | 7.60% |
| PetVivo | -3,817.65% | -99.68% | -82.24% |
Insider & Institutional Ownership
内部人与机构所有权
90.5% of Boston Scientific shares are held by institutional investors. Comparatively, 13.7% of PetVivo shares are held by institutional investors. 0.7% of Boston Scientific shares are held by company insiders. Comparatively, 35.3% of PetVivo shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
波士顿科学公司90.5%的股份由机构投资者持有。相比之下，PetVivo 13.7%的股份由机构投资者持有。波士顿科学公司0.7%的股份由公司内部人士持有。相比之下，PetVivo 35.3%的股份由公司内部人士持有。强大的机构持股表明，捐赠基金、对冲基金和大型基金管理公司相信，一家公司的长期表现将好于大盘。
Valuation and Earnings
估值和收益
This table compares Boston Scientific and PetVivo's top-line revenue, earnings per share (EPS) and valuation.
该表格比较了波士顿科学公司和PetVivo的营收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Boston Scientific | $11.89 billion | 4.95 | $1.04 billion | $0.58 | 70.95 |
| PetVivo | $120,000.00 | 209.96 | -$5.01 million | ($0.75) | -3.35 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 波士顿科学公司 | 118.9亿美元 | 4.95 | 10.4亿美元 | $0.58 | 70.95 |
| PetVivo | $120,000.00 | 209.96 | -501万元 | ($0.75) | -3.35 |
Boston Scientific has higher revenue and earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
波士顿科学公司的收入和收益比PetVivo更高。PetVivo的市盈率低于波士顿科学公司，这表明它目前是两只股票中更负担得起的一只。
Volatility & Risk
波动性与风险
Boston Scientific has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, PetVivo has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500.
Boston Science的贝塔系数为0.85，表明其股价的波动性比标准普尔500指数低15%。相比之下，PetVivo的贝塔系数为1.96，这表明其股价的波动性比标准普尔500指数高96%。
Summary
摘要
Boston Scientific beats PetVivo on 10 of the 14 factors compared between the two stocks.
波士顿科学公司在比较两只股票的14个因素中有10个超过了PetVivo。
About Boston Scientific
关于波士顿科学公司
(Get Rating)
(获取评级)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
波士顿科学公司开发、制造和营销医疗设备，用于世界各地的各种介入医学专科。它通过三个部分运作：Medsurg，Rhythm and Neuro和心血管。该公司提供诊断和治疗胃肠道和肺部疾病的设备；治疗各种泌尿和盆腔疾病的设备；植入式心脏复律和植入式心脏再同步治疗除颤器；起搏器和植入式心脏再同步治疗起搏器；以及远程患者管理系统。它还提供诊断和治疗心脏频率和节律紊乱的医疗技术，包括3D心脏标测和导航解决方案、消融导管、诊断导管、标测导管、心内超声导管、分娩鞘和其他附件；用于治疗慢性疼痛的脊髓刺激器系统；间接减压系统；以及脑深部刺激系统。此外，该公司还提供介入心脏病学产品，包括用于治疗冠状动脉疾病的药物洗脱冠状动脉支架系统；用于治疗动脉粥样硬化的经皮冠状动脉介入产品；用于冠状动脉和心腔以及各种外周血管的血管内导管定向超声成像导管、部分血流储备设备和系统；以及结构性心脏治疗。此外，它还提供用于治疗动脉疾病的支架、球囊导管、导线和动脉粥样硬化系统；用于治疗静脉疾病的血栓切除和声学脉冲溶栓系统、导线和支架；用于治疗癌症的外周栓塞器、放射性微球、消融系统、冷冻治疗消融系统以及微型和引流导管。该公司成立于1979年，总部设在马尔伯勒。, 马萨诸塞州。
About PetVivo
关于PetVivo
(Get Rating)
(获取评级)
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
PetVivo控股公司是一家生物医疗设备公司，从事用于治疗动物疾病和疾病的医疗设备和生物材料的制造、商业化和许可。它的主要产品是Spryng，一种由兽医管理的关节内注射，用于治疗跛行和其他关节疾病，如狗和马的骨关节炎。该公司的流水线产品还包括17种用于兽医和人类临床应用的治疗设备。PetVivo控股公司成立于2009年，总部设在明尼苏达州明尼阿波利斯市。
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
接受《波士顿科学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对波士顿科学公司及相关公司评级的每日简要摘要。